摘要 |
PURPOSE: A method for improving QT dispersion and heart rate variability using corticotrophin releasing factor (CRF) antagonists is provided to prevent sudden death in specific patients, particularly those suffering from cardiovascular or heart related diseases such as hypertension, tachycardia, congestive heart failure and the like, as well as other diseases such as stroke, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, colonic hypersensitivity associated with psychopathological disturbance. CONSTITUTION: The objective medicine contains a therapeutically effective amount of a corticotrophin releasing factor antagonist such as a compound of Formula I or II or a pharmaceutically acceptable salt thereof, wherein the dashed line represents an optional double bond; A is N or CR7 (R7 is H, a 1-4C alkyl, or the like); B is NR1R2, CR1R2R11 (R1 is H or a 1-6C alkyl; R2 is a 1-6C alkyl, an aryl, or the like; R11 is H, hydroxy, or the like), or the like; D is N, CR10 (R10 is H, a 1-6C alkyl, or the like), or the like; E is N, CR4 (R4 is H, a 1-6C alkyl, or the like), or the like; Z is NH, O, S, or the like; R3 is H, a halogen, a 1-6C alkyl, or the like; R5 is phenyl, naphthyl, or the like), e.g. 4-(1-ethyl-propoxy)-2,5-dimethyl-6-(2,4,6-trimethyl- benzyl)-pyrimidine. The daily administration rate of the compound is preferably 1.0-20 mg/kg body-weight.
|